Monoclonal antibodies for treating osteoporosis

References

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–795.
   PubMed Web of Science ®Google Scholar
• Brunetti G, Di Benedetto A, Mori G. Bone remodeling. In: Albanese C, Faletti C, eds. Imaging of prosthetic joints—a combined radiological and clinical perspective. Milan: Springer; 2014. p. 27–37. ISBN: 978-88-470-5482-0.
   Google Scholar
• Kylmaoja E, Nakamura M, Tuukkanen J. Osteoclasts and remodeling based bone formation. Curr Stem Cell Res Ther. 2016;11(8):626–633.
   PubMed Web of Science ®Google Scholar
• Seeman E. Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr. 2009;19(3):219–233.
   PubMed Web of Science ®Google Scholar
• Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965;206(983):489–490.
   PubMed Web of Science ®Google Scholar
• Epker BN, Frost HM. Periosteal appositional bone growth from age two to age seventy in man. A tetracycline evaluation. Anat Rec. 1966;154:573–577.
   PubMedGoogle Scholar
• Ruff CB, Hayes WC. Subperiosteal expansion and cortical remodeling of the human femur and tibia with aging. Science. 1982;217:945–948.
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318–3325.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–419.
   PubMed Web of Science ®Google Scholar
• Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017;96:29–37.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–176.
   PubMed Web of Science ®Google Scholar
• Mori G, D’Amelio P, Faccio R, et al. The interplay between the bone and the immune system. Clin Dev Immunol. 2013;2013:720504.
   PubMed Web of Science ®Google Scholar
• Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–323.
   PubMed Web of Science ®Google Scholar
• Ventura A, Brunetti G, Colucci S, et al. Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed Res Int. 2013;2013:1–8.
   Web of Science ®Google Scholar
• Brunetti G, Rizzi R, Oranger A, et al. LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. Oncotarget. 2014;5(24):12950–12967.
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12):1481–1488.
   PubMed Web of Science ®Google Scholar
• Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci US A. 1999;96(7):3540–3545.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–319.
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490–495.
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875–4882.
   PubMed Web of Science ®Google Scholar
• Prolia [package insert]. Thousand Oaks, CA: Amgen, Inc; 2016.
   Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132–5139.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castrationresistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822.
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
   PubMed Web of Science ®Google Scholar
• Zebaze RM, Libanati C, Austin M, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173–179.
   PubMed Web of Science ®Google Scholar
• McClung MR, Lippuner K, Brandi ML, et al. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. Osteoporos Int. 2017 Jul 26;28:2967–2973. [Epub ahead of print]. DOI:10.1007/s00198-017-4140-y
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–831.
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483–4492.
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Libanati C, Niu QT, et al. Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab. J Bone Miner Res. 2015;30(7):1280–1289.
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25(10):2256–2265.
   PubMed Web of Science ®Google Scholar
• Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27(7):1462–1470.
   PubMed Web of Science ®Google Scholar
• Pelle DW, Ringler JW, Peacock JD, et al. Targeting receptoractivator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response. Transl Res J Lab Clinb Med. 2014;164(2):139–148.
   Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523.
   PubMed Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–56.
   PubMed Web of Science ®Google Scholar
• Leder BZ, Tsai JN, Uihlein AV, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99:1694–1700.
   PubMed Web of Science ®Google Scholar
• Idolazzi L, Rossini M, Viapiana O, et al. Teriparatide and denosumab combination therapy and skeletal metabolism. Osteoporos Int. 2016;27:3301–3307.
   PubMed Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Burnett-Bowie SA, et al. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study. J Bone Miner Res. 2015;30:39–45.
   PubMed Web of Science ®Google Scholar
• Tsai JN, Uihlein AV, Burnett-Bowie SM, et al. Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016;101:2023–2030.
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–980.
   PubMed Web of Science ®Google Scholar
• Kennedy OD, Herman BC, Laudier DM, et al. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone. 2012;50(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016;27(5):1917–1921.
   PubMed Web of Science ®Google Scholar
• Koldkjaer Solling AS, Harslof T, Kaal A, et al. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2016;27(7):2383–2386.
   PubMed Web of Science ®Google Scholar
• Gossai N, Hilgers MV, Polgreen LE, et al. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078–1080.
   PubMed Web of Science ®Google Scholar
• Setsu N, Kobayashi E, Asano N, et al. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab. 2016;34(1):118–122.
   PubMed Web of Science ®Google Scholar
• Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect—a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24–32.
   PubMed Web of Science ®Google Scholar
• Grasemann C, Schundeln MM, Hovel M, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab. 2013;98(8):3121–3126.
   PubMed Web of Science ®Google Scholar
• Wang HD, Boyce AM, Tsai JY, et al. Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab. 2014;99(3):891–897.
   PubMed Web of Science ®Google Scholar
• Brown JP, Roux C, Torring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–752.
   PubMed Web of Science ®Google Scholar
• Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, et al. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int J. 2016;27(5):1923–1925.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291–1296.
   PubMed Web of Science ®Google Scholar
• Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab. 2017;102(2):354–358.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Terpos E. Clinical vertebral fractures following denosumab discontinuation. Endocrine. 2016;54(1):271–272.
   PubMed Web of Science ®Google Scholar
• Kostenuik PJ, Smith SY, Samadfam R, et al. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys. J Bone Miner Res. 2015;30(4):657–669.
   PubMed Web of Science ®Google Scholar
• Ominsky MS, Stouch B, Schroeder J, et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone. 2011;49(2):162–173.
   PubMed Web of Science ®Google Scholar
• Ruffoni D, Fratzl P, Roschger P, et al. The bone mineralization density distribution as a fingerprint of the mineralization process. Bone. 2007;40(5):1308–1319.
   PubMed Web of Science ®Google Scholar
• Fuchs RK, Faillace ME, Allen MR, et al. Bisphosphonates do not alter the rate of secondary mineralization. Bone. 2011;49(4):701–705.
   PubMed Web of Science ®Google Scholar
• Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25:1886–1894.
   PubMed Web of Science ®Google Scholar
• Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–161.
   PubMed Web of Science ®Google Scholar
• Furuya Y, Inagaki A, Khan M, et al. Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-kB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem. 2013;288(8):5562–5571.
   PubMed Web of Science ®Google Scholar
• Fan Y, Hanai JI, Le PT, et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab. 2017;25(3):661–672.
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Rizzi R, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood. 2004;104:3722–3730.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Brunetti G, Colucci S, et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab. 2009;94(7):2269–2276.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Brunetti G, Ventura A, et al. Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner’s Syndrome. Bone. 2015;81:228–236.
   PubMed Web of Science ®Google Scholar
• Brunetti G, Papadia F, Tummolo A, et al. Impaired bone remodeling in children with osteogenesis imperfecta treated and untreated with bisphosphonates: the role of DKK1, RANKL, and TNF-α. Osteoporos Int. 2016;27(7):2355–2365.
   PubMed Web of Science ®Google Scholar
• Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–755.
   PubMed Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(30):4875–4882.
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–1132.
   PubMed Web of Science ®Google Scholar
• XGEVA® (denosumab) prescribing information. Amgen.
   Google Scholar
• Xgeva [package insert]. Thousand Oaks, CA: Amgen, Inc; 2016.
   Google Scholar
• Semler O, Netzer C, Hoyer-Kuhn H, et al. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183–188.
   PubMed Web of Science ®Google Scholar
• Hoyer-Kuhn H, Netzer C, Koerber F, et al. Two years’ experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9:145.
   PubMed Web of Science ®Google Scholar
• Ward L, Bardai G, Moffatt P, et al. Osteogenesis imperfecta type VI in individuals from Northern Canada. Calcif Tissue Int. 2016;98(6):566–572.
   PubMed Web of Science ®Google Scholar
• Brunetti G, Marzano F, Colucci S, et al. Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene. Endocrine. 2012;42(2):266–271.
   PubMed Web of Science ®Google Scholar
• Naidu A, Malmquist MP, Denham CA, et al. Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg. 2014;72(12):2469–2484.
   PubMed Web of Science ®Google Scholar
• Lange T, Stehling C, Frohlich B, et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J. 2013;22(6):1417–1422.
   PubMed Web of Science ®Google Scholar
• Pelle DW, Ringler JW, Peacock JD, et al. Targeting receptoractivator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response. Transl Res J Lab Clin Med. 2014;164(2):139–148.
   Google Scholar
• Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537–543.
   PubMed Web of Science ®Google Scholar
• Balemans W, Van Den Ende J, Freire Paes-Alves A, et al. Localization of the gene for sclerosteosis to the van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet. 1999;64(6):1661–1669.
   PubMed Web of Science ®Google Scholar
• Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19(2):179–192.
   PubMed Web of Science ®Google Scholar
• Poole KE, Van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb J. 2005;19(13):1842–1844.
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860–869.
   PubMed Web of Science ®Google Scholar
• Tu X, Rhee Y, Condon KW, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50(1):209–217.
   PubMed Web of Science ®Google Scholar
• Rhee Y, Allen MR, Condon K, et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intra-cortical remodeling. J Bone Miner Res. 2011;26(5):1035–1046.
   PubMed Web of Science ®Google Scholar
• Niziolek PJ, MacDonald BT, Kedlaya R, et al. High bone mass-causing mutant LRP5 receptors are resistant to endogenous inhibitors in vivo. J Bone Miner Res. 2015;30(10):1822–1830.
   PubMed Web of Science ®Google Scholar
• Kramer I, Loots GG, Studer A, et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010;25(2):178–189.
   PubMed Web of Science ®Google Scholar
• Faienza MF, Ventura A, Delvecchio M, et al. High sclerostin and Dickkopf-1 (DKK-1) serum levels in children and adolescents with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2017;102(4):1174–1181.
   PubMed Web of Science ®Google Scholar
• Tsentidis C, Gourgiotis D, Kossiva L, et al. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density. Osteoporos Int. 2017;28(3):945–953.
   PubMed Web of Science ®Google Scholar
• Giordano P, Brunetti G, Lassandro G, et al. High serum sclerostin levels in children with haemophilia A. Br J Haematol. 2016;172(2):293–295.
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J. 2011;1(6):e27.
   PubMedGoogle Scholar
• Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer. 2012;131:1466–1471.
   PubMed Web of Science ®Google Scholar
• Eda H, Santo L, Wein MN, et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease. J Bone Miner Res. 2016;31:1225–1234.
   PubMed Web of Science ®Google Scholar
• McDonald MM, Reagan MR, Youlten SE, et al. Inhibiting the osteocyte specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017;129:3452–3464.
   PubMed Web of Science ®Google Scholar
• Delgado-Calle J, Anderson J, Cregor MD, et al. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017. in press. DOI:10.1038/leu.2017.152
   PubMed Web of Science ®Google Scholar
• McClung MR. Clinical utility of anti-sclerostin antibodies. Bone. 2017;96:3–7.
   PubMed Web of Science ®Google Scholar
• Padhi D, Allison M, Kivitz AJ, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2014;54(2):168–178.
   PubMed Web of Science ®Google Scholar
• Padhi D, Jang G, Stouch B, et al. Single-dose, placebo controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–420.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–1543.
   PubMed Web of Science ®Google Scholar
• Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585–1594.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427.
   PubMed Web of Science ®Google Scholar
• Amgen. Amgen and UCB announce topline phase 3 data from activecomparator study of EVENITY (romosozumab) in postmenopausal women with osteoporosis. 2017 May 21 [cited 2017 Jun 22]. Available from: https://www.amgen.com/media/newsreleases/2017/05/amgenanducbannouncetoplinephase3datafromactivecomparatorstudyofevenityromosozumabinpostmenopausalwomenwithosteoporosis/
   Google Scholar
• Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005;90(12):6392–6395.
   PubMed Web of Science ®Google Scholar
• van Lierop AH, Hamdy NA, Hamersma H, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26(12):2804–2811.
   PubMed Web of Science ®Google Scholar
• van Lierop AH, Hamdy NA, van Egmond ME, et al. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2013;28(4):848–854.
   PubMed Web of Science ®Google Scholar
• Ge X, Wang X. Role of Wnt canonical pathway in haematological malignancies. J Hematol Oncol. 2010;3:33.
   PubMed Web of Science ®Google Scholar
• Oranger A, Brunetti G, Colaianni G, et al. Sclerostin stimulates angiogenesis in human endothelial cells. Bone. 2017;101:26–36.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, D’Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 2015;88(2):235–240.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A. Romosozumab in postmenopausal women with osteopenia. N Engl J Med. 2014;370(17):1664–1665.
   PubMed Web of Science ®Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312–321.
   PubMed Web of Science ®Google Scholar
• Chouinard L, Felx M, Mellal N, et al. Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmacol. 2016;81:212–222.
   PubMed Web of Science ®Google Scholar
• Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–733.
   PubMed Web of Science ®Google Scholar
• Jolette J, Attalla B, Varela A, et al. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34). Regul Toxicol Pharmacol. 2017;86:356–365.
   PubMed Web of Science ®Google Scholar
• Tankó LB, Goldhahn J, Varela A, et al. Does activin receptor blockade by bimagrumab (BYM338) pose detrimental effects on bone healing in a rat fibula osteotomy model? Calcif Tissue Int. 2016;99(3):310–321.
   PubMed Web of Science ®Google Scholar